(Total Views: 520)
Posted On: 03/27/2020 12:44:13 PM
Post# of 145879
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
If Leronlimab is a viable option and prevents mortality and continues to prove that it prevents mortality in a high percentage of the patients that it is used on through the emergency IND, then I think it will be used and made available to as many US patients as possible. I think that with the current circumstances in the hospitals and country, it would be used for patients in the phase 2 clinical trial, and then the people that fall outside of the clinical trial, I believe they will put in a relaxed or broader emergency IND use.
If CytoDyn had 24,000 vials on hand and another 100,000 in production from Samsung, with a 6 week course, this could be used for roughly 20,666 patients.
At this time I do not think money would be the issue to secure the ramp up of leronlimab. I think with the given circumstances and the relaxed lending from banks, securing the product would not be an issue.
If CytoDyn had 24,000 vials on hand and another 100,000 in production from Samsung, with a 6 week course, this could be used for roughly 20,666 patients.
At this time I do not think money would be the issue to secure the ramp up of leronlimab. I think with the given circumstances and the relaxed lending from banks, securing the product would not be an issue.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)